Dossier
insulin glargine
Coverage of insulin glargine in the Nexus archive.
- STAT+: Popular insulin product enters shortage as other pens leave market
Sanofi's Lantus Solostar insulin pen is experiencing supply issues due to increased demand, causing patients to struggle to find medication. The FDA does not classify the situation as a shortage, but Sanofi is accelerating production to address the problem.
- Add-On Orforglipron: Good News for Type 2 Diabetes and Inadequate Glycemic Control
Once-daily orforglipron improved outcomes in adults with type 2 diabetes and inadequate glycemic control, according to the ACHIEVE-5 trial. The drug is an add-on treatment for patients already on insulin glargine.